Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer

Seong-Keun Yoo,Young Shin Song,Eun Kyung Lee,Jinha Hwang,Hwan Hee Kim,Gyeongseo Jung,Young A Kim,Su-jin Kim,Sun Wook Cho,Jae-Kyung Won,Eun-Jae Chung,Jong-Yeon Shin,Kyu Eun Lee,Jong-Il Kim,Young Joo Park,Jeong-Sun Seo
DOI: https://doi.org/10.1038/s41467-019-10680-5
IF: 16.6
2019-06-24
Nature Communications
Abstract:Anaplastic thyroid cancer (ATC) and advanced differentiated thyroid cancers (DTCs) show fatal outcomes, unlike DTCs. Here, we demonstrate mutational landscape of 27 ATCs and 86 advanced DTCs by massively-parallel DNA sequencing, and transcriptome of 13 ATCs and 12 advanced DTCs were profiled by RNA sequencing. TERT, AKT1, PIK3CA, and EIF1AX were frequently co-mutated with driver genes (BRAFV600E and RAS) in advanced DTCs as well as ATC, but tumor suppressors (e.g., TP53 and CDKN2A) were predominantly altered in ATC. CDKN2A loss was significantly associated with poor disease-specific survival in patients with ATC or advanced DTCs, and up-regulation of CD274 (PD-L1) and PDCD1LG2 (PD-L2). Transcriptome analysis revealed a fourth molecular subtype of thyroid cancer (TC), ATC-like, which hardly reflects the molecular signatures in DTC. Furthermore, the activation of JAK-STAT signaling pathway could be a potential druggable target in RAS-positive ATC. Our findings provide insights for precision medicine in patients with advanced TCs.
multidisciplinary sciences
What problem does this paper attempt to address?